Indapamide

Indapamide is a thiazide-like diuretic taken by mouth. The US label read is for indapamide tablets and lists two uses: the treatment of hypertension, alone or in combination with other antihypertensive drugs, and the treatment of salt and fluid retention associated with congestive heart failure. No brand-name indapamide label was found in openFDA, so this page rests on a generic manufacturer's label. The label's separate passage on diuretics in pregnancy was not recorded.

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 5764; UNII F089I0511L. MeSH descriptor D007190 is Indapamide. Class: Thiazide-like Diuretic (FDA established pharmacologic class, RxClass). The label read is the indapamide tablets, Rising Pharma Holdings, Inc. label, effective 2023-06-26 in openFDA (application ANDA074461). Other indapamide labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 3 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
3
Phase 3 or 4
2
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedUnknown statusAll statuses
Phase 2101
Phase 4112
All phases213

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of indapamide tablets, in the Rising Pharma Holdings, Inc. version dated 2023-06-26 in openFDA, lists the medicine for the treatment of hypertension, alone or in combination with other antihypertensive drugs, and for the treatment of salt and fluid retention associated with congestive heart failure.

    Applies to Recipient not specified People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for indapamide tablets, Rising Pharma Holdings, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0687ed93-4761-4f9c-887d-95309c03f60e (manufacturer Rising Pharma Holdings, Inc., application ANDA074461), returned on 2026-11-09. The label text is dated 2023-06-26 (effective_time). Other openFDA records of indapamide labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2023-06-26
      Source state
      Current
      Version fingerprint
      f5d1e4a29dcccd9463f8c6ba4ab5a58c972367d951fddb28fa5c9bf7b86e3c43
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for indapamide tablets, Rising Pharma Holdings, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0687ed93-4761-4f9c-887d-95309c03f60e (manufacturer Rising Pharma Holdings, Inc., application ANDA074461), returned on 2026-11-09. The label text is dated 2023-06-26 (effective_time). Other openFDA records of indapamide labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20230626.
      Retrieved
      Source effective date
      2023-06-26
      Source state
      Current
      Version fingerprint
      f5d1e4a29dcccd9463f8c6ba4ab5a58c972367d951fddb28fa5c9bf7b86e3c43
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

LOZOL

No label from the application holder was found in the openFDA label dataset for application NDA018538. This page does not show another labeler's label in its place.

WIDAPLIK

No label from the application holder was found in the openFDA label dataset for application NDA219423. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA018538 LOZOL
  2. Supplemental approval NDA018538 LOZOL
  3. Approval NDA219423 WIDAPLIK

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA018538

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA219423

Record details

Record id
cardio:indapamide
Content hash
fd18e64fc98c979899df809427ca829d29c921ea8394766c35f548e227a22ec1